“冬病夏治”—中医“治未病”的理论与实践
|
摘要
临床部分
目的
根据中医“治未病”理论和春夏养阳、秋冬养阴的观点,采用“冬病夏治”穴位敷贴疗法防治缓解期小儿哮喘。通过观察经验方喘敷灵贴剂三伏穴位(大椎、双侧定喘、双侧肺俞、双侧脾俞、双侧肾俞)敷贴对缓解期哮喘患儿临床症状,红细胞C3b受体花环率(RBC-C3bRR),红细胞免疫复合物受体花环率(RBC-ICR),肿瘤坏死因子(TNF-α),非特异性免疫球蛋白E(IgE),集落刺激因子(GM-CSF),Thl、Th2细胞因子IFN-Y、IL-4的影响,并与疗效确切的布地奈德气雾剂比较,探讨中药喘敷灵贴剂穴位敷贴防治缓解期小儿哮喘的临床疗效及其作用机理,以证实“冬病夏治”疗法的科学性、有效性。
方法
选取60例病例均来自2009年7月湖北省中医院儿科门诊就诊患儿,符合中、西医小儿哮喘缓解期诊断标准及病例纳入标准。将所有病例随机分为喘敷灵贴剂三伏穴位敷贴组和布地奈德气雾剂口服防治组,每组各30例。所有患儿均按中医哮喘缓解期分型标准及病情分级标准进行中医分型和病情严重程度分级。对两组患儿的性别、年龄、发病年龄、病程、病情、中医辨证分型等进行比较,经统计学处理P>0.05,无显著性差异,具有可比性。观察期从2009年7月～2010年7月,共一年。观察组患儿分别在头伏、二伏、三伏的第一天以喘敷灵贴剂敷贴患儿背部大椎、双侧定喘、双侧肺俞、双侧脾俞、双侧肾俞等穴位；对照组单纯给予布地奈德气雾剂200μg/次,12小时一次,连续3月。此外,患儿于第一次敷贴前及观察期结束后分别检测TNF-α、IgE、GM-CSF、IFN-γ、IL-4、RBC-C3bRR、RBC-ICR水平,比较上述指标的变化情况。
结果
1.两组治疗后均能明显改善缓解期哮喘患儿的临床症状(P<0.01),两组之间比较无明显差异(P>0.05)；
2.观察组不同年龄段、不同病程及不同中医证型组患儿治疗前后临床症状的改善,经组间比较无明显差异(P>0.05)；
3.两组均能显著升高缓解期哮喘患儿RBC-C3bRR和降低RBC-ICR水平(P<0.05),两组之间比较无明显差异(P>0.05)；
4.两组均能显著降低缓解期哮喘患儿血清非特异性IgE水平(P<0.01)和TNF-α水平(P<0.01),两组之间比较无明显差异(P>0.05)；
5.两组均能显著降低缓解期哮喘患儿GM-CSF水平(P<0.05),两组之间比较无明显差异(P>0.05)；
6.两组均能显著降低IL-4、升高IFN-γ水平(P<0.05),两组之间比较无明显差异(P>0.05)。
结论
1.喘敷灵可显著改善红细胞免疫功能,减少炎性介质的释放；
2.喘敷灵可调节患儿的细胞免疫状态,提高患儿免疫能力及抵抗力,改善症状和降低哮喘发作次数,减轻哮喘发作程度。其机制可能是通过调节患儿T淋巴细胞的功能,从而调节T淋巴细胞分泌的IL-4、IFN-Y及其他细胞因子水平,抑制患儿IgE的合成来实现的；
3.喘敷灵防治哮喘疗效确切,剂量准确,使用简便、卫生经济,值得临床推广应用。
实验部分
目的
观察中药穴位敷贴治疗改善过敏性鼻炎大鼠的搔鼻、喷嚏、鼻溢等症状,促进过敏性鼻炎大鼠的生长发育,改善过敏性鼻炎大鼠通气功能,降低过敏性鼻炎大鼠IgE及ECP水平,调节血清IL-2、IL-4、IL-6、INF-Y水平及ICAM-1、VCAM-1等指标的表达水平,从细胞分子水平探讨中药穴位敷贴对过敏性鼻炎的免疫调节机制,为科学有效地治疗过敏性鼻炎提供理论依据,证实“冬病夏治”疗法的科学性、有效性。
方法
本研究将SD幼年大鼠随机分成4组：正常对照组、过敏性鼻炎模型组、地塞米松口服组、穴位敷贴组。
敷贴药物组成：皂荚、白芥子、黄芪、辛夷花、苍耳子、细辛、延胡索、生姜汁。
穴位选取：大椎、肺俞、脾俞、内关。
采用双抗夹心ELISA法比较各组免疫球蛋白E(IgE)、嗜酸性粒细胞阳离子蛋白(ECP)水平及细胞因子(IL-2、IL-4、IL-6、IFN-γ)、细胞间粘附分子-1(ICAM-1)、血管细胞粘附分子-1(VCAM-1)的表达水平,观察各组鼻粘膜组织的病理改变及大鼠鼻粘膜中的嗜酸性粒细胞数、中性粒细胞数和淋巴细胞数。
结果
1.实验组与模型组IgE水平比较,P<0.01,有显著统计学意义；
2.西药组与模型组IgE水平比较,P<0.01,有显著统计学意义；
3.实验组与西药组IgE水平比较,P<0.05,有统计学意义；
4.实验组与模型组ECP水平比较,P<0.01,有显著统计学意义；
5.西药组与模型组ECP水平比较,P<0.05,有统计学意义；
6.实验组与西药组ECP水平比较,P>0.05,无显著统计学意义；
7.实验组与模型组IL-2水平比较,P<0.01,有显著统计学意义；
8.西药组与模型组IL-2水平比较,P<0.01,有显著统计学意义；
9.实验组与西药组IL-2水平比较,P>0.05,无显著统计学意义；
10.实验组与模型组ICAM-1水平比较,P<0.01,有显著统计学意义；
11.西药组与模型组ICAM-1水平比较,P<0.01,有显著统计学意义；
12.实验组与西药组ICAM-1水平比较,P<0.05,有统计学意义。
结论
实验研究表明：实验组与模型组均能有效降低IgE水平,且实验组与西药组比较有统计学意义；实验组与模型组均能有效降低ECP水平,但实验组较明显；实验组与模型组均能有效升高IL-2水平,但实验组较明显；实验组与模型组均能有效降低ICAM-1水平,且实验组与西药组比较有统计学意义。
THE PART OF CLINICAL OBSERVATION
OBJECTIVE
According to TCM theory and the treatment of disease based on the concept of Yang Yang in the spring and summer, Yang Yin in the autumn and winter, the use of Winter Disease Control Point Application therapy in children with asthma in remission. Through the observation experience square patches volts meridians (Da Zhui, bilateral Dingchuan, bilateral Feishu, bilateral spleen, bilateral Shenshu) Application on the clinical symptoms of asthmatic children, red blood cell C3b receptor rosette (RBC-C3bRR), red blood cell receptor immune complex rosette (RBC-ICR), tumor necrosis factor-α(TNF-α), non-specific immunoglobulin E, colony stimulating factor (GM-CSF), Thl, Th2 cells factor IFN-γ, IL-4 in vitro and deposited with the effect of the exact spirit of the traditional formulations of asthma(paste) to compare, apply spirit of traditional Chinese medicine asthma control point application patches remission of asthma in children and its possible role in clinical mechanism, so as to apply the Spirit of Chinese medicine formulations of asthma improved the feasibility and provide the basis for clinical application.
METHODS
60 cases were selected from July 2009 in Hubei Province Chinese Medicine Hospital pediatric outpatient children, in line with Western diagnostic criteria for children with asthma in remission and case inclusion criteria. Will apply in all cases randomly assigned to breathe Point Application Dog Days soul patch group and Budesonide Aerosol treatment group,30 patients in each group.All asthmatic patients in remission according to Chinese standards and classification of disease type classification standard for traditional Chinese medicine and disease classification. Two groups of children on gender, age, onset age, duration of disease, illness, TCM syndrome were compared, the statistical P>0.05, no significant differences between comparable. Observation period started from July 2009 to July 2010 only, a total of one year. Group of children were observed during the first V, the second V, volts) deposited on the first day to breathe a soul patch applicator children back Ojo, bilateral Dingchuan, bilateral Feishu, bilateral spleen, and other points of bilateral Shenshu; control group were given Budesonide Aerosol 200μg/times,12 hours, even for 3 months. In addition, patients in the first applicator before and after the observation period were used to detect RBC-C3bRR, RBC-ICR, TNF-α, IgE, GM-CSF, IFN-Y, IL-4 levels were compared before and after treatment the changes in these indicators.
RESULTS
1. After treatment, could significantly improve the remission of clinical symptoms in asthmatic children(P<0.01), no significant difference between the two groups (P>0.05);
2. Observe the groups of different ages, different course and different set of TCM clinical symptoms in children improved after no significant difference between groups (P>0.05);
3. Both groups can significantly eleated children remission asthma RBC-C3bRR and reduce RBC-ICR level (P< 0.05), no significant difference between the two groups (P>0.05);
4. Significantly decreased in both groups asthmatic non-specific IgE serum levels (P<0.01) and TNF-αlevels (P<0.01), no significant difference between the two groups (P>0.05);
5. Significantly decreased in both groups asthmatic children wi th GM-CSF levels (P<0.05), no significant difference between the two groups (P>0.05);
6. The blood in both groups significantly decreased IL-4, increased IFN-γlevels (P<0.05), no significant difference between the two groups (P>0.05).
CONCLUSION
1. Dyspnea can significantly improve the spiritual deposited immune function, reduce the release of inflammatory mediators to control asthma attacks;
2. Panting spirit adjustable deposited cellular immune status of children, improve immunity and resistance in children, reduce the number of colds and asthma attacks degree, reduce the degree of asthma attacks.The mechanism may be by regulating T cell function in children, thereby regulating T lymphocyte secretion of IL-4, IFN-γand other cytokines, inhibiting the synthesis of IgE in children to achieve;
3. Asthma is effective against the disease spirit deposited, the dose is accurate, easy to use, health economics, is worthy of clinical application.
THE PART OF EXPERIMENTAL RESEARCH
OBJECTIVE
Observe the effects of point application mainly to improve the treatment of allergic rhinitis in rats scratching the nose, sneezing, rhinorrhea and other symptoms of allergic rhinitis in rats to promote the growth and development, to improve ventilatory function in rats with allergic rhinitis, allergic rhinitis, decreased IgE and ECP level of regulation of serum IL-2, IL-4, IL-6, INF-γlevels and ICAM-1, VCAM-1 expression levels and other indicators, From the cellular and molecular level of Acupoint Application on the immune regulation of allergic rhinitis mechanism for scientific and effective treatment of allergic rhinitis provide a theoretical basis.
METHODS
In this study, young SD rats were randomly divided into four groups:normal control group (control group), model group (model group), oral dexamethasone group (group B), point application group (experimental group).
Sticking drugs:Chinese honey locust, Sinapis alba, Huang Qi, The lily magnolia is colored, Achene of xanthium sibiricum, Asarum, Fumitory, Ginger juice.
Point selection:Ojo, Feishu, spleen, internal relations.
Double antibody sandwich ELISA method in each group immunoglobulin E (IgE), eosinophil cationic protein(ECP) levels and cytokines (IL-2, IL-4, IL-6, IFN-γ),cells adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) expression. Nasal mucosa were observed pathological changes and rat nasal mucosa in the number of eosinophils, neutrophils and lymphocytes.
RESULTS
1. Experimental group and model group than in the IgE, P<0.01, there was significant;
2. Western group and model group than in the IgE, P<0.01, there was significant;
3.Experimental group and the western medicine group than in the IgE, P<0.05, statistically significant;
4. Experimental group and model group than in the ECP, P<0.01, there was significant;
5. Western group and model group than in the ECP, P<0.05, statistically significant;
6. Experimental group and the western medicine group than in the ECP, P>0.05, no statistically significant;
7. Experimental group and model group than in the IL-2, P<0.01, there was significant;
8. Western group and model group than in the IL-2, P<0.01, there was significant;
9. Experimental group and WM group than in the IL-2, P>0.05, no statistically significant;
10. Experimental group and model group than in the ICAM-1, P<0.01, there was significant;
11. Western group and model group than in the ICAM-1, P<0.01, there was significant;
12. Experimental group and WM group than in the ICAM-1, P<0.05, statistically significant.
CONCLUSION
Experimental studies have shown:the experimental group and model group can effectively reduce IgE levels, and the experimental group and western medicine group were statistically significant; experimental group and model group can effectively reduce the ECP level, but the experimental group was more apparent; experimental group and model group can effectively increase IL-2 levels, but the experimental group was more apparent; experimental group and model group can effectively reduce the level of ICAM-1, and the experimental group and western medicine group were statistically significant.
目的
根据中医“治未病”理论和春夏养阳、秋冬养阴的观点,采用“冬病夏治”穴位敷贴疗法防治缓解期小儿哮喘。通过观察经验方喘敷灵贴剂三伏穴位(大椎、双侧定喘、双侧肺俞、双侧脾俞、双侧肾俞)敷贴对缓解期哮喘患儿临床症状,红细胞C3b受体花环率(RBC-C3bRR),红细胞免疫复合物受体花环率(RBC-ICR),肿瘤坏死因子(TNF-α),非特异性免疫球蛋白E(IgE),集落刺激因子(GM-CSF),Thl、Th2细胞因子IFN-Y、IL-4的影响,并与疗效确切的布地奈德气雾剂比较,探讨中药喘敷灵贴剂穴位敷贴防治缓解期小儿哮喘的临床疗效及其作用机理,以证实“冬病夏治”疗法的科学性、有效性。
方法
选取60例病例均来自2009年7月湖北省中医院儿科门诊就诊患儿,符合中、西医小儿哮喘缓解期诊断标准及病例纳入标准。将所有病例随机分为喘敷灵贴剂三伏穴位敷贴组和布地奈德气雾剂口服防治组,每组各30例。所有患儿均按中医哮喘缓解期分型标准及病情分级标准进行中医分型和病情严重程度分级。对两组患儿的性别、年龄、发病年龄、病程、病情、中医辨证分型等进行比较,经统计学处理P>0.05,无显著性差异,具有可比性。观察期从2009年7月～2010年7月,共一年。观察组患儿分别在头伏、二伏、三伏的第一天以喘敷灵贴剂敷贴患儿背部大椎、双侧定喘、双侧肺俞、双侧脾俞、双侧肾俞等穴位；对照组单纯给予布地奈德气雾剂200μg/次,12小时一次,连续3月。此外,患儿于第一次敷贴前及观察期结束后分别检测TNF-α、IgE、GM-CSF、IFN-γ、IL-4、RBC-C3bRR、RBC-ICR水平,比较上述指标的变化情况。
结果
1.两组治疗后均能明显改善缓解期哮喘患儿的临床症状(P<0.01),两组之间比较无明显差异(P>0.05)；
2.观察组不同年龄段、不同病程及不同中医证型组患儿治疗前后临床症状的改善,经组间比较无明显差异(P>0.05)；
3.两组均能显著升高缓解期哮喘患儿RBC-C3bRR和降低RBC-ICR水平(P<0.05),两组之间比较无明显差异(P>0.05)；
4.两组均能显著降低缓解期哮喘患儿血清非特异性IgE水平(P<0.01)和TNF-α水平(P<0.01),两组之间比较无明显差异(P>0.05)；
5.两组均能显著降低缓解期哮喘患儿GM-CSF水平(P<0.05),两组之间比较无明显差异(P>0.05)；
6.两组均能显著降低IL-4、升高IFN-γ水平(P<0.05),两组之间比较无明显差异(P>0.05)。
结论
1.喘敷灵可显著改善红细胞免疫功能,减少炎性介质的释放；
2.喘敷灵可调节患儿的细胞免疫状态,提高患儿免疫能力及抵抗力,改善症状和降低哮喘发作次数,减轻哮喘发作程度。其机制可能是通过调节患儿T淋巴细胞的功能,从而调节T淋巴细胞分泌的IL-4、IFN-Y及其他细胞因子水平,抑制患儿IgE的合成来实现的；
3.喘敷灵防治哮喘疗效确切,剂量准确,使用简便、卫生经济,值得临床推广应用。
实验部分
目的
观察中药穴位敷贴治疗改善过敏性鼻炎大鼠的搔鼻、喷嚏、鼻溢等症状,促进过敏性鼻炎大鼠的生长发育,改善过敏性鼻炎大鼠通气功能,降低过敏性鼻炎大鼠IgE及ECP水平,调节血清IL-2、IL-4、IL-6、INF-Y水平及ICAM-1、VCAM-1等指标的表达水平,从细胞分子水平探讨中药穴位敷贴对过敏性鼻炎的免疫调节机制,为科学有效地治疗过敏性鼻炎提供理论依据,证实“冬病夏治”疗法的科学性、有效性。
方法
本研究将SD幼年大鼠随机分成4组：正常对照组、过敏性鼻炎模型组、地塞米松口服组、穴位敷贴组。
敷贴药物组成：皂荚、白芥子、黄芪、辛夷花、苍耳子、细辛、延胡索、生姜汁。
穴位选取：大椎、肺俞、脾俞、内关。
采用双抗夹心ELISA法比较各组免疫球蛋白E(IgE)、嗜酸性粒细胞阳离子蛋白(ECP)水平及细胞因子(IL-2、IL-4、IL-6、IFN-γ)、细胞间粘附分子-1(ICAM-1)、血管细胞粘附分子-1(VCAM-1)的表达水平,观察各组鼻粘膜组织的病理改变及大鼠鼻粘膜中的嗜酸性粒细胞数、中性粒细胞数和淋巴细胞数。
结果
1.实验组与模型组IgE水平比较,P<0.01,有显著统计学意义；
2.西药组与模型组IgE水平比较,P<0.01,有显著统计学意义；
3.实验组与西药组IgE水平比较,P<0.05,有统计学意义；
4.实验组与模型组ECP水平比较,P<0.01,有显著统计学意义；
5.西药组与模型组ECP水平比较,P<0.05,有统计学意义；
6.实验组与西药组ECP水平比较,P>0.05,无显著统计学意义；
7.实验组与模型组IL-2水平比较,P<0.01,有显著统计学意义；
8.西药组与模型组IL-2水平比较,P<0.01,有显著统计学意义；
9.实验组与西药组IL-2水平比较,P>0.05,无显著统计学意义；
10.实验组与模型组ICAM-1水平比较,P<0.01,有显著统计学意义；
11.西药组与模型组ICAM-1水平比较,P<0.01,有显著统计学意义；
12.实验组与西药组ICAM-1水平比较,P<0.05,有统计学意义。
结论
实验研究表明：实验组与模型组均能有效降低IgE水平,且实验组与西药组比较有统计学意义；实验组与模型组均能有效降低ECP水平,但实验组较明显；实验组与模型组均能有效升高IL-2水平,但实验组较明显；实验组与模型组均能有效降低ICAM-1水平,且实验组与西药组比较有统计学意义。
THE PART OF CLINICAL OBSERVATION
OBJECTIVE
According to TCM theory and the treatment of disease based on the concept of Yang Yang in the spring and summer, Yang Yin in the autumn and winter, the use of Winter Disease Control Point Application therapy in children with asthma in remission. Through the observation experience square patches volts meridians (Da Zhui, bilateral Dingchuan, bilateral Feishu, bilateral spleen, bilateral Shenshu) Application on the clinical symptoms of asthmatic children, red blood cell C3b receptor rosette (RBC-C3bRR), red blood cell receptor immune complex rosette (RBC-ICR), tumor necrosis factor-α(TNF-α), non-specific immunoglobulin E, colony stimulating factor (GM-CSF), Thl, Th2 cells factor IFN-γ, IL-4 in vitro and deposited with the effect of the exact spirit of the traditional formulations of asthma(paste) to compare, apply spirit of traditional Chinese medicine asthma control point application patches remission of asthma in children and its possible role in clinical mechanism, so as to apply the Spirit of Chinese medicine formulations of asthma improved the feasibility and provide the basis for clinical application.
METHODS
60 cases were selected from July 2009 in Hubei Province Chinese Medicine Hospital pediatric outpatient children, in line with Western diagnostic criteria for children with asthma in remission and case inclusion criteria. Will apply in all cases randomly assigned to breathe Point Application Dog Days soul patch group and Budesonide Aerosol treatment group,30 patients in each group.All asthmatic patients in remission according to Chinese standards and classification of disease type classification standard for traditional Chinese medicine and disease classification. Two groups of children on gender, age, onset age, duration of disease, illness, TCM syndrome were compared, the statistical P>0.05, no significant differences between comparable. Observation period started from July 2009 to July 2010 only, a total of one year. Group of children were observed during the first V, the second V, volts) deposited on the first day to breathe a soul patch applicator children back Ojo, bilateral Dingchuan, bilateral Feishu, bilateral spleen, and other points of bilateral Shenshu; control group were given Budesonide Aerosol 200μg/times,12 hours, even for 3 months. In addition, patients in the first applicator before and after the observation period were used to detect RBC-C3bRR, RBC-ICR, TNF-α, IgE, GM-CSF, IFN-Y, IL-4 levels were compared before and after treatment the changes in these indicators.
RESULTS
1. After treatment, could significantly improve the remission of clinical symptoms in asthmatic children(P<0.01), no significant difference between the two groups (P>0.05);
2. Observe the groups of different ages, different course and different set of TCM clinical symptoms in children improved after no significant difference between groups (P>0.05);
3. Both groups can significantly eleated children remission asthma RBC-C3bRR and reduce RBC-ICR level (P< 0.05), no significant difference between the two groups (P>0.05);
4. Significantly decreased in both groups asthmatic non-specific IgE serum levels (P<0.01) and TNF-αlevels (P<0.01), no significant difference between the two groups (P>0.05);
5. Significantly decreased in both groups asthmatic children wi th GM-CSF levels (P<0.05), no significant difference between the two groups (P>0.05);
6. The blood in both groups significantly decreased IL-4, increased IFN-γlevels (P<0.05), no significant difference between the two groups (P>0.05).
CONCLUSION
1. Dyspnea can significantly improve the spiritual deposited immune function, reduce the release of inflammatory mediators to control asthma attacks;
2. Panting spirit adjustable deposited cellular immune status of children, improve immunity and resistance in children, reduce the number of colds and asthma attacks degree, reduce the degree of asthma attacks.The mechanism may be by regulating T cell function in children, thereby regulating T lymphocyte secretion of IL-4, IFN-γand other cytokines, inhibiting the synthesis of IgE in children to achieve;
3. Asthma is effective against the disease spirit deposited, the dose is accurate, easy to use, health economics, is worthy of clinical application.
THE PART OF EXPERIMENTAL RESEARCH
OBJECTIVE
Observe the effects of point application mainly to improve the treatment of allergic rhinitis in rats scratching the nose, sneezing, rhinorrhea and other symptoms of allergic rhinitis in rats to promote the growth and development, to improve ventilatory function in rats with allergic rhinitis, allergic rhinitis, decreased IgE and ECP level of regulation of serum IL-2, IL-4, IL-6, INF-γlevels and ICAM-1, VCAM-1 expression levels and other indicators, From the cellular and molecular level of Acupoint Application on the immune regulation of allergic rhinitis mechanism for scientific and effective treatment of allergic rhinitis provide a theoretical basis.
METHODS
In this study, young SD rats were randomly divided into four groups:normal control group (control group), model group (model group), oral dexamethasone group (group B), point application group (experimental group).
Sticking drugs:Chinese honey locust, Sinapis alba, Huang Qi, The lily magnolia is colored, Achene of xanthium sibiricum, Asarum, Fumitory, Ginger juice.
Point selection:Ojo, Feishu, spleen, internal relations.
Double antibody sandwich ELISA method in each group immunoglobulin E (IgE), eosinophil cationic protein(ECP) levels and cytokines (IL-2, IL-4, IL-6, IFN-γ),cells adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) expression. Nasal mucosa were observed pathological changes and rat nasal mucosa in the number of eosinophils, neutrophils and lymphocytes.
RESULTS
1. Experimental group and model group than in the IgE, P<0.01, there was significant;
2. Western group and model group than in the IgE, P<0.01, there was significant;
3.Experimental group and the western medicine group than in the IgE, P<0.05, statistically significant;
4. Experimental group and model group than in the ECP, P<0.01, there was significant;
5. Western group and model group than in the ECP, P<0.05, statistically significant;
6. Experimental group and the western medicine group than in the ECP, P>0.05, no statistically significant;
7. Experimental group and model group than in the IL-2, P<0.01, there was significant;
8. Western group and model group than in the IL-2, P<0.01, there was significant;
9. Experimental group and WM group than in the IL-2, P>0.05, no statistically significant;
10. Experimental group and model group than in the ICAM-1, P<0.01, there was significant;
11. Western group and model group than in the ICAM-1, P<0.01, there was significant;
12. Experimental group and WM group than in the ICAM-1, P<0.05, statistically significant.
CONCLUSION
Experimental studies have shown:the experimental group and model group can effectively reduce IgE levels, and the experimental group and western medicine group were statistically significant; experimental group and model group can effectively reduce the ECP level, but the experimental group was more apparent; experimental group and model group can effectively increase IL-2 levels, but the experimental group was more apparent; experimental group and model group can effectively reduce the level of ICAM-1, and the experimental group and western medicine group were statistically significant.
引文
[1]李俊德.中医“治未病”的科学内涵和精髓[J].世界中西医结合杂志,2007,2(3)：125～126.
[2]李兰珍,朱向东,王燕.中医治未病思想源流考析[J].中医研究,2008,21(7)：57～59.
[3]张志斌,王永炎.试论中医“治未病”之概念及其科学内容[J].北京中医药大学学报,2007,30(7)：440～444.
[4]张岚.“治未病”的历史文化探源[J].四川中医,2008,26(9)：124125.
[5]冯文林,吴弥漫.《内经》“治未病”治则的思想探源[J].中国中医基础医学杂志,2006,12(12)：886～887.
[6]蒋宏杰。华佗“治未病”思想浅析[J].安徽中医临床杂志,2002,14(3)：207.
[7]唐乾利,岳桂华.“治未病”对中医院发展机遇及问题探析[J].中国中医药信息杂志,2008,15(6)：4～6.
[8]王化猛.《老子》未病思想探析[J].安徽中医学院学报,1999,18(6)：10～11.
[9]吴弥漫.“治未病”贯彻“以人为本”理念的中医防治疾病思想[J].新中医,2007,39(5)：1～3.
[10]刘盛,陈万生,乔传卓等.不同种质板蓝根和大青叶的抗甲型流感病毒作用[J].第二军医大学学报,2000,3(35)：204～205.
[11]唐凯.经方合用治慢性乙型肝炎高胆红素血症40例[J].国医论坛,2002,17(1)：6.
[12]中药大词典[M].上海科技出版社,第1版,1985,6.
[13]王联庆.祖国医学中预防医学浅论[J].长春中医药学院学报,1997,13：11～12.
[14]那莎,龙子江,王宗殿等.栀子总皂苷对肝郁脾虚型慢性肝炎大鼠血液流变学的影响[J].江苏中医药,2005,26(1)：52～54.
[15]陈敏.中医膏方在亚健康人群中的临床应用[J].中国现代临床医学,2008,7(9)：61～62.
[16]王琦.9种基本中医体质类型的分类及其诊断表述依据[J].北京中医药大学学报,2005,28(4)：1.
[17]李真,冯晓东,张铭.六经体质学说及其对治未病的意义[J].江苏中医药,2008,40(11)：105～106.
[18]董丽萍.中医体质学说与疾病的关系[J].中国中医基础医学杂志,2006,12(11)：859～860.
[19]王琦.体质辨识是“治未病”的“抓手”.环球中医药.
[20]程洁,李忠仁.针灸治未病的古代文献研究[J].江西中医学院学报.2002,14(3)：49～51.
[21]周章玲,等.人体保健经穴的探讨[J].中国临床康复,2003,7(9)：1458～1459.
[22]林晓天,李元林.推拿治疗亚健康状态探析[J].辽宁中医杂志,2001,28(11)：687～688.
[23]巫善东,巫善金.推拿预防感冒30例之我见[J].按摩与导引,2001,4,17(2)：34～35,38.
[24]吴杰,虞坚尔,闵伟福.从中医“治未病”浅谈小儿哮喘的防治[J].中医文献杂志,27～28.
[25]韩丽,谯凤英.穴位敷贴防治儿童过敏性鼻炎30例[J].福建中医药,2009,40(3)：15～16.
[26]赵杜娟.冬令健脾补肾膏方防治支气管哮喘58例[J].江西中医药,2006,6(37)： 22～24.
[27]蒉纲,楼映.唐汉钧教授运用膏方防治外科病的经验[J].中华中医药杂志,2007,22(10)：695～697.
[28]岳炜,陈润清,吴静欢.运用中医药膳防治妇科疾病[J].光明中医,2007,22(8)：29～31.
[29]刘英君.冬季常喝药茶,防治时令疾病.维普资讯.
[30]樊树英.中药浴剂开发的前景[J].中国中医药信息杂志,1995,2： 20.
[31]付文录.肾脏病的中医外治法[J].山东中医杂志,1992,11(3)：62.
[32]李宏运,王周伍.冬病夏治、夏病冬治机理探微[J].国医论坛,2006,21(4)：17～18.
[33]叶玉妹.“冬病夏治”治未病——叶景华咳喘粉外敷治疗慢性支气管炎[J].中医药通报,2008,2(7)：11～13.
[34]周峻伟,苑惠清,王和天.从“天人相应”、“治未病”理论探讨“冬病夏治”治疗咳喘病的依据[J].中医论坛,2008,8(5)：1070～1072.
[35]李志勤,秦艳虹.冬病夏治在哮喘治疗中的临床运用[J].山西中医学院学报,2009,10(4)：2～3.
[1]国家中医药管理局,中华人民共和国中医药行业标准中医病证诊断疗效标准.南京大学出版社,1994：77
[2]汪受传主编.中医儿科学(第七版).中国中医药出版社,北京,2002年8月：75～81
[3]全国儿童哮喘防治协作组.儿童哮喘诊断治疗常规(试行方案).中华儿科杂志,1998,36(12)：747
[4]中华医学会：《支气管哮喘防治指南》.中华医学会呼吸病学分会哮喘学组.2008版
[5]王吉耀.内科学[M].2005年第1版.北京：人民卫生出版社
[6]周仲瑛主编.中医内科学[M].2003年7月第1版.北京：中国中医药出版社
[7]郭峰.红细胞免疫及其调节功能测定方法[J].免疫学杂志,1990,6(1)：61～65
[8]Siegel I, Linliu T, Gleicher N. The red-cell immune system. Lancet, 1981,2 (8246):556-558
[9]郭峰,张延东.血清对红细胞免疫粘附抑制作用的测定[J].上海免疫学杂志,1987,7(3)：133～135
[10]王利民.过敏性哮喘患者IgE高亲合力受体和低亲合力受体的变化.中华微生物学和免疫学杂志,1998(增)：51～53
[11]李明华.气道变应性炎症与支气管哮喘.国外医学内科学分册,1990,6：258～262
[12]谢柏梅.地塞米松雾化吸入对哮喘患者诱导痰液中ECP、TNF-α、SIL-2R水平的影响.陕西医学杂志,2010,1：33～34
[13]邵金莲.ACQ、FEV1%和外周血EOS对临床哮喘控制的指导意义.实用医学杂志,2010,18：3329～3331
[14]BorishL, Rosenwasser LJ. JAllergy Cl in Immunol,1996,97: 719-753
[15]黄花荣.哮喘患儿外周血CD4+CD25+调节性T细胞的变化及其与哮喘病情的关系.新医学,2009,4：221～223
[16]Kopt M,Le-Gios G,Bachmann M, et al. Disruption of murine IL-4 geneblocks Th2 cytokine responses.Nature,1993,362:245
[17]Umetsu DT, Dekruytt RH.Th1 and Th2 CD4 in human allergic disease. J Allergy Clin Immunol,1997,100:1-6
[18]Chretien I,Pene J,Briene F, et al.Eur J Immunol.1990,20:243
[19]陈艳.黄芪在树突状细胞水平对哮喘平衡的调节作用.中华微生物和免疫学杂志,2008,12：1064～1069
[20]李明华,杨丽华.与支气管哮喘发病有关的细胞因子.国外医学内科学分册,1997,24(12)：507～512
[21]Walker C, et al.Am Rev ResPir Dis,1992,146:109-115
[22]狄亚珍,夏萍,陈伟君.高危哮喘儿血清中IL-4、IFN-γ及总IgE的测定及其临床意义.临床儿科杂志,2000,18(4)：222～224
[23]王群,林江涛,孙洪涛.哮喘患者TH亚群的失衡及相关细胞因子、肺通气功能改变的相关性研究.中华结核和呼吸杂志,2000,23(3)：147～150
[1]顾之燕主编.耳鼻喉科变应性和免疫性疾病,天津：天津科学出版社,2000
[2]SIH T, MIONO. Allergic rhinitis in the child and associated comorbidities [J]. Pediatr Al lergy Immuno,2009 Aug (2). Epub ahead of print
[3]刘应波,程冬兰.广东佛山市顺德区乐从镇过敏性鼻炎儿童发病情况及其生活质量的调查[J].新医学,2010,41(5)：293～295
[4]冯纬纭.过敏性鼻炎口服液对常年性变态反应性鼻炎S-IgE表达的影响[J].中国中西医结合杂志,2010,04(30)：435～436
[5]李延忠.细胞黏附分子及一氧化氮合酶在变应性鼻炎鼻黏膜中的表达[J].临床耳鼻咽喉科杂志,2006,04(20)：315～318
[6]Nouri-Aria KT,O'Brien F, Noble W, et al. Cytokine expression during allergen-induced Late nasal responses:IL-4 and IL-5 mRNA is expressed early (at 6h) predominantly by eosinophils [J].Clin Exp Allergy,2000,30:1709-1716
[7]苏贻心,郭履,陆培,等.过敏性鼻炎患儿IL-4、IL-10、IFN-γ水平的检测[J].上海免疫学杂志,1999,19(1)：44
[8]Tanbe S, Kinuta Y, Yasumatsu H, et al. Effects of cit-rus unshiu powder on the cytokine balance in peripheral blood mononuclear cells of patients with seasonal allergic rhinitis to pollen [J].Biosci Biotechnol Biochem,2007,71:2852-2855
[9]郎笑梅.夏季穴位敷贴治疗过敏性鼻炎30例[J].中医药临床杂志,2007,19(1)：31～32
[10]李园,李佩文.中药外用透皮吸收研究进展[J].医学理论与实践,1999,12(6)：367～369
[11]张仲源.促进透皮吸收的中药[J].中医外治杂志,2001(10)3：48～49
[12]陈靖,李添应,冯烁强,等.变应性鼻炎患者外周血单个棱细胞变应原刺激与白细胞介素4和13表达的关系[J].中华耳鼻咽喉科杂志,2004,39(12)：758～759
[13]洪苏玲,黄江菊,杨玉成.变应性鼻炎患者血清中4种细胞因子的检测[J].中华耳鼻咽喉科杂志,2002,37(4)：312～313.
[1]李俊德.中医“治未病”的科学内涵和精髓[J].世界中西医结合杂志,2007,2(3)：125～126.
[2]李兰珍,朱向东,王燕.中医治未病思想源流考析[J].中医研究,2008,21(7)：57～59.
[3]张志斌,王永炎.试论中医“治未病”之概念及其科学内容[J].北京中医药大学学报,2007,30(7)：440～444.
[4]张岚.“治未病”的历史文化探源[J].四川中医,2008,26(9)：124～125.
[5]冯文林,吴弥漫.《内经》“治未病”治则的思想探源[J].中国中医基础医学杂志,2006,12(12)：886～887.
[6]蒋宏杰.华佗“治未病”思想浅析[J].安徽中医临床杂志,2002,14(3)：207.
[7]金志甲主编.内经[M].陕西中医学院,湖南科学技术出版社,2005,2月第一版.
[8]金光亮.《内经》未病概念与“治未病”理论探讨[J].北京中医药大学学报,2006,29(12)：804～806.
[9]唐乾利,岳桂华.“治未病”对中医院发展机遇及问题探析[J].中国中医药信息杂志,2008,15(6)：4-6.
[10]王化猛.《老子》未病思想探析[J].安徽中医学院学报,1999,18(6)：10～11.
[11]蓝毓营.“治未病”源流述略[J].上海中医药杂志,2005,39(9)：11～12.
[12]王国强.努力构建“治未病”中医特色服务体系[J].紫光阁,2008,16(6)：35～36.
[13]王琦等.中医体质学[M].北京：中国医药科技出版社,1995.
[14]王琦.9种基本中医体质类型的分类及其诊断表述依据[J].北京中医药大学学报,2005,28(4)：1～8.
[15]毛婷婷.“治未病”理论及临床研究进展[J].当代医学,2009,15(4)：13～15.
[2]李兰珍,朱向东,王燕.中医治未病思想源流考析[J].中医研究,2008,21(7)：57～59.
[3]张志斌,王永炎.试论中医“治未病”之概念及其科学内容[J].北京中医药大学学报,2007,30(7)：440～444.
[4]张岚.“治未病”的历史文化探源[J].四川中医,2008,26(9)：124125.
[5]冯文林,吴弥漫.《内经》“治未病”治则的思想探源[J].中国中医基础医学杂志,2006,12(12)：886～887.
[6]蒋宏杰。华佗“治未病”思想浅析[J].安徽中医临床杂志,2002,14(3)：207.
[7]唐乾利,岳桂华.“治未病”对中医院发展机遇及问题探析[J].中国中医药信息杂志,2008,15(6)：4～6.
[8]王化猛.《老子》未病思想探析[J].安徽中医学院学报,1999,18(6)：10～11.
[9]吴弥漫.“治未病”贯彻“以人为本”理念的中医防治疾病思想[J].新中医,2007,39(5)：1～3.
[10]刘盛,陈万生,乔传卓等.不同种质板蓝根和大青叶的抗甲型流感病毒作用[J].第二军医大学学报,2000,3(35)：204～205.
[11]唐凯.经方合用治慢性乙型肝炎高胆红素血症40例[J].国医论坛,2002,17(1)：6.
[12]中药大词典[M].上海科技出版社,第1版,1985,6.
[13]王联庆.祖国医学中预防医学浅论[J].长春中医药学院学报,1997,13：11～12.
[14]那莎,龙子江,王宗殿等.栀子总皂苷对肝郁脾虚型慢性肝炎大鼠血液流变学的影响[J].江苏中医药,2005,26(1)：52～54.
[15]陈敏.中医膏方在亚健康人群中的临床应用[J].中国现代临床医学,2008,7(9)：61～62.
[16]王琦.9种基本中医体质类型的分类及其诊断表述依据[J].北京中医药大学学报,2005,28(4)：1.
[17]李真,冯晓东,张铭.六经体质学说及其对治未病的意义[J].江苏中医药,2008,40(11)：105～106.
[18]董丽萍.中医体质学说与疾病的关系[J].中国中医基础医学杂志,2006,12(11)：859～860.
[19]王琦.体质辨识是“治未病”的“抓手”.环球中医药.
[20]程洁,李忠仁.针灸治未病的古代文献研究[J].江西中医学院学报.2002,14(3)：49～51.
[21]周章玲,等.人体保健经穴的探讨[J].中国临床康复,2003,7(9)：1458～1459.
[22]林晓天,李元林.推拿治疗亚健康状态探析[J].辽宁中医杂志,2001,28(11)：687～688.
[23]巫善东,巫善金.推拿预防感冒30例之我见[J].按摩与导引,2001,4,17(2)：34～35,38.
[24]吴杰,虞坚尔,闵伟福.从中医“治未病”浅谈小儿哮喘的防治[J].中医文献杂志,27～28.
[25]韩丽,谯凤英.穴位敷贴防治儿童过敏性鼻炎30例[J].福建中医药,2009,40(3)：15～16.
[26]赵杜娟.冬令健脾补肾膏方防治支气管哮喘58例[J].江西中医药,2006,6(37)： 22～24.
[27]蒉纲,楼映.唐汉钧教授运用膏方防治外科病的经验[J].中华中医药杂志,2007,22(10)：695～697.
[28]岳炜,陈润清,吴静欢.运用中医药膳防治妇科疾病[J].光明中医,2007,22(8)：29～31.
[29]刘英君.冬季常喝药茶,防治时令疾病.维普资讯.
[30]樊树英.中药浴剂开发的前景[J].中国中医药信息杂志,1995,2： 20.
[31]付文录.肾脏病的中医外治法[J].山东中医杂志,1992,11(3)：62.
[32]李宏运,王周伍.冬病夏治、夏病冬治机理探微[J].国医论坛,2006,21(4)：17～18.
[33]叶玉妹.“冬病夏治”治未病——叶景华咳喘粉外敷治疗慢性支气管炎[J].中医药通报,2008,2(7)：11～13.
[34]周峻伟,苑惠清,王和天.从“天人相应”、“治未病”理论探讨“冬病夏治”治疗咳喘病的依据[J].中医论坛,2008,8(5)：1070～1072.
[35]李志勤,秦艳虹.冬病夏治在哮喘治疗中的临床运用[J].山西中医学院学报,2009,10(4)：2～3.
[1]国家中医药管理局,中华人民共和国中医药行业标准中医病证诊断疗效标准.南京大学出版社,1994：77
[2]汪受传主编.中医儿科学(第七版).中国中医药出版社,北京,2002年8月：75～81
[3]全国儿童哮喘防治协作组.儿童哮喘诊断治疗常规(试行方案).中华儿科杂志,1998,36(12)：747
[4]中华医学会：《支气管哮喘防治指南》.中华医学会呼吸病学分会哮喘学组.2008版
[5]王吉耀.内科学[M].2005年第1版.北京：人民卫生出版社
[6]周仲瑛主编.中医内科学[M].2003年7月第1版.北京：中国中医药出版社
[7]郭峰.红细胞免疫及其调节功能测定方法[J].免疫学杂志,1990,6(1)：61～65
[8]Siegel I, Linliu T, Gleicher N. The red-cell immune system. Lancet, 1981,2 (8246):556-558
[9]郭峰,张延东.血清对红细胞免疫粘附抑制作用的测定[J].上海免疫学杂志,1987,7(3)：133～135
[10]王利民.过敏性哮喘患者IgE高亲合力受体和低亲合力受体的变化.中华微生物学和免疫学杂志,1998(增)：51～53
[11]李明华.气道变应性炎症与支气管哮喘.国外医学内科学分册,1990,6：258～262
[12]谢柏梅.地塞米松雾化吸入对哮喘患者诱导痰液中ECP、TNF-α、SIL-2R水平的影响.陕西医学杂志,2010,1：33～34
[13]邵金莲.ACQ、FEV1%和外周血EOS对临床哮喘控制的指导意义.实用医学杂志,2010,18：3329～3331
[14]BorishL, Rosenwasser LJ. JAllergy Cl in Immunol,1996,97: 719-753
[15]黄花荣.哮喘患儿外周血CD4+CD25+调节性T细胞的变化及其与哮喘病情的关系.新医学,2009,4：221～223
[16]Kopt M,Le-Gios G,Bachmann M, et al. Disruption of murine IL-4 geneblocks Th2 cytokine responses.Nature,1993,362:245
[17]Umetsu DT, Dekruytt RH.Th1 and Th2 CD4 in human allergic disease. J Allergy Clin Immunol,1997,100:1-6
[18]Chretien I,Pene J,Briene F, et al.Eur J Immunol.1990,20:243
[19]陈艳.黄芪在树突状细胞水平对哮喘平衡的调节作用.中华微生物和免疫学杂志,2008,12：1064～1069
[20]李明华,杨丽华.与支气管哮喘发病有关的细胞因子.国外医学内科学分册,1997,24(12)：507～512
[21]Walker C, et al.Am Rev ResPir Dis,1992,146:109-115
[22]狄亚珍,夏萍,陈伟君.高危哮喘儿血清中IL-4、IFN-γ及总IgE的测定及其临床意义.临床儿科杂志,2000,18(4)：222～224
[23]王群,林江涛,孙洪涛.哮喘患者TH亚群的失衡及相关细胞因子、肺通气功能改变的相关性研究.中华结核和呼吸杂志,2000,23(3)：147～150
[1]顾之燕主编.耳鼻喉科变应性和免疫性疾病,天津：天津科学出版社,2000
[2]SIH T, MIONO. Allergic rhinitis in the child and associated comorbidities [J]. Pediatr Al lergy Immuno,2009 Aug (2). Epub ahead of print
[3]刘应波,程冬兰.广东佛山市顺德区乐从镇过敏性鼻炎儿童发病情况及其生活质量的调查[J].新医学,2010,41(5)：293～295
[4]冯纬纭.过敏性鼻炎口服液对常年性变态反应性鼻炎S-IgE表达的影响[J].中国中西医结合杂志,2010,04(30)：435～436
[5]李延忠.细胞黏附分子及一氧化氮合酶在变应性鼻炎鼻黏膜中的表达[J].临床耳鼻咽喉科杂志,2006,04(20)：315～318
[6]Nouri-Aria KT,O'Brien F, Noble W, et al. Cytokine expression during allergen-induced Late nasal responses:IL-4 and IL-5 mRNA is expressed early (at 6h) predominantly by eosinophils [J].Clin Exp Allergy,2000,30:1709-1716
[7]苏贻心,郭履,陆培,等.过敏性鼻炎患儿IL-4、IL-10、IFN-γ水平的检测[J].上海免疫学杂志,1999,19(1)：44
[8]Tanbe S, Kinuta Y, Yasumatsu H, et al. Effects of cit-rus unshiu powder on the cytokine balance in peripheral blood mononuclear cells of patients with seasonal allergic rhinitis to pollen [J].Biosci Biotechnol Biochem,2007,71:2852-2855
[9]郎笑梅.夏季穴位敷贴治疗过敏性鼻炎30例[J].中医药临床杂志,2007,19(1)：31～32
[10]李园,李佩文.中药外用透皮吸收研究进展[J].医学理论与实践,1999,12(6)：367～369
[11]张仲源.促进透皮吸收的中药[J].中医外治杂志,2001(10)3：48～49
[12]陈靖,李添应,冯烁强,等.变应性鼻炎患者外周血单个棱细胞变应原刺激与白细胞介素4和13表达的关系[J].中华耳鼻咽喉科杂志,2004,39(12)：758～759
[13]洪苏玲,黄江菊,杨玉成.变应性鼻炎患者血清中4种细胞因子的检测[J].中华耳鼻咽喉科杂志,2002,37(4)：312～313.
[1]李俊德.中医“治未病”的科学内涵和精髓[J].世界中西医结合杂志,2007,2(3)：125～126.
[2]李兰珍,朱向东,王燕.中医治未病思想源流考析[J].中医研究,2008,21(7)：57～59.
[3]张志斌,王永炎.试论中医“治未病”之概念及其科学内容[J].北京中医药大学学报,2007,30(7)：440～444.
[4]张岚.“治未病”的历史文化探源[J].四川中医,2008,26(9)：124～125.
[5]冯文林,吴弥漫.《内经》“治未病”治则的思想探源[J].中国中医基础医学杂志,2006,12(12)：886～887.
[6]蒋宏杰.华佗“治未病”思想浅析[J].安徽中医临床杂志,2002,14(3)：207.
[7]金志甲主编.内经[M].陕西中医学院,湖南科学技术出版社,2005,2月第一版.
[8]金光亮.《内经》未病概念与“治未病”理论探讨[J].北京中医药大学学报,2006,29(12)：804～806.
[9]唐乾利,岳桂华.“治未病”对中医院发展机遇及问题探析[J].中国中医药信息杂志,2008,15(6)：4-6.
[10]王化猛.《老子》未病思想探析[J].安徽中医学院学报,1999,18(6)：10～11.
[11]蓝毓营.“治未病”源流述略[J].上海中医药杂志,2005,39(9)：11～12.
[12]王国强.努力构建“治未病”中医特色服务体系[J].紫光阁,2008,16(6)：35～36.
[13]王琦等.中医体质学[M].北京：中国医药科技出版社,1995.
[14]王琦.9种基本中医体质类型的分类及其诊断表述依据[J].北京中医药大学学报,2005,28(4)：1～8.
[15]毛婷婷.“治未病”理论及临床研究进展[J].当代医学,2009,15(4)：13～15.